他克莫司联合激素在重症肌无力患者中的效果及对IFN-γ IL-4和TGF-β的影响OACSTPCD

Objective To investigate the therapeutic effect of tacrolimus combined with steroids in patients with myasthenia gravis(MG)and its effect on interferon-γ(IFN-γ),interleukin-4(IL-4)and transforming growth factor-β(TGF-β).Methods Totally 96 MG patients from May 2022 to September 2023 in the the First Affiliated Hospital of Zhengzhou University were selected as the subjects,and were divided into two groups using envelope method,with 48 cases in each group.The control group received hormone therapy,while the observation group received combined treatment with tacrolimus.Both groups completed a 4-week treatment.The MG-activities of daily living profile(MG-ADL),QMGS scale,biochemical indicators,and safety were compared between the two groups.Results After intervention,the MG-ADL score of observation group(2.95±0.79)was lower than that of the control group(4.59±1.12),(P<0.05),and the QMGS score of observation group(8.51±1.69)was lower than that of the control group(12.69±2.24),(P<0.05).After intervention,the daily life and muscle strength of the two groups were improved,and fatigue tolerance was enhanced,and the improvement was more obvious in the observation group than that in the control group.The IFN-γ(43.96±3.18)in the observation group was lower than that in the control group(52.58±3.63),(P<0.05),and the IL-4(36.89±6.39)in the observation group was higher than that in the control group(31.11±6.42),(P<0.05).After intervention,TGF-β in observation group was higher than that in control group(P<0.05).There was no statistical difference in the incidence of adverse reactions between the observation group(10.42%)and the control group(6.25%),(P>0.05).Conclusion The combination of tacrolimus and steroids has a significant effect on the treatment of MG patients,which can improve the quality of daily life,reduce MG-ADL and QMGS scores,improve biochemical indicators,and have high treatment safety.It is worth of promoting.